|
2021 Journal Article A prospective study investigating the efficacy and toxicity of definitive ChemoRadiation and ImmunOtherapy (CRIO) in locally and/or regionally advanced unresectable cutaneous squamous cell carcinomaLin, Charles, Ballah, Trishna, Nottage, Michelle, Hay, Karen, Chua, Benjamin, Kenny, Lizbeth, Thomas, Paul, Teng, Michele, Keller, Jacqui, Le, Trang, Edmunds, Jennifer and Hughes, Brett (2021). A prospective study investigating the efficacy and toxicity of definitive ChemoRadiation and ImmunOtherapy (CRIO) in locally and/or regionally advanced unresectable cutaneous squamous cell carcinoma. Radiation Oncology, 16 (1) 69, 1-13. doi: 10.1186/s13014-021-01795-5 |
|
2021 Journal Article Randomized trial of radiation therapy with weekly cisplatin or cetuximab in low-risk HPV-associated oropharyngeal cancer (TROG 12.01) – A Trans-Tasman Radiation Oncology Group StudyRischin, Danny, King, Madeleine, Kenny, Lizbeth, Porceddu, Sandro, Wratten, Christopher, Macann, Andrew, Jackson, James E., Bressel, Mathias, Herschtal, Alan, Fisher, Richard, Fua, Tsien, Lin, Charles, Liu, Chen, Hughes, Brett G.M., McGrath, Margaret, McDowell, Lachlan and Corry, June (2021). Randomized trial of radiation therapy with weekly cisplatin or cetuximab in low-risk HPV-associated oropharyngeal cancer (TROG 12.01) – A Trans-Tasman Radiation Oncology Group Study. International Journal of Radiation: Oncology - Biology - Physics, 111 (4), 876-886. doi: 10.1016/j.ijrobp.2021.04.015 |
|
2021 Journal Article The identification of circulating tumour DNA using MassARRAY technology in non-small-cell lung cancer (NSCLC)Kulasinghe, Arutha, O'Leary, Connor, Monkman, James, Bharti, Vandhana, Irwin, Darryl, Dutta, Sanjay, Richard, Derek J., Hughes, Brett, Ladwa, Rahul and O'Byrne, Ken (2021). The identification of circulating tumour DNA using MassARRAY technology in non-small-cell lung cancer (NSCLC). Lung Cancer, 160, 73-77. doi: 10.1016/j.lungcan.2021.08.005 |
|
2021 Journal Article Health-related quality of life of patients with recurrent or metastatic cutaneous squamous cell carcinoma treated with Pembrolizumab in KEYNOTE-629Hughes, Brett G. M., Mendoza, Rene Gonzalez, Basset-Seguin, Nicole, Vornicova, Olga, Schachter, Jacob, Joshi, Abhishek, Meyer, Nicolas, Grange, Florent, Piulats, Josep M., Bauman, Jessica R., Chirovsky, Diana, Zhang, Pingye, Gumuscu, Burak, Swaby, Ramona F. and Grob, Jean-Jacques (2021). Health-related quality of life of patients with recurrent or metastatic cutaneous squamous cell carcinoma treated with Pembrolizumab in KEYNOTE-629. Dermatology and Therapy, 11 (5), 1777-1790. doi: 10.1007/s13555-021-00598-6 |
|
2021 Journal Article Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysisRischin, Danny, Khushalani, Nikhil I., Schmults, Chrysalyne D., Guminski, Alexander, Chang, Anne Lynn S., Lewis, Karl D., Lim, Annette M., Hernandez-Aya, Leonel, Hughes, Brett G. M., Schadendorf, DIrk, Hauschild, Axel, Thai, Alesha A., Stankevich, Elizabeth, Booth, Jocelyn, Yoo, Suk-Young, Li, Siyu, Chen, Zhen, Okoye, Emmanuel, Chen, Chieh-I, Mastey, Vera, Sasane, Medha, Lowy, Israel, Fury, Matthew G. and Migden, Michael R. (2021). Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. Journal for ImmunoTherapy of Cancer, 9 (8) e002757, e002757. doi: 10.1136/jitc-2021-002757 |
|
2021 Journal Article Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trialHughes, B. G. M., Munoz-Couselo, E., Mortier, L., Bratland, Å., Gutzmer, R., Roshdy, O., González Mendoza, R., Schachter, J., Arance, A., Grange, F., Meyer, N., Joshi, A., Billan, S., Zhang, P., Gumuscu, B., Swaby, R. F. and Grob, J.-J. (2021). Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial. Annals of Oncology, 32 (10), 1276-1285. doi: 10.1016/j.annonc.2021.07.008 |
|
2021 Conference Publication Phase 2 study of pembrolizumab (pembro) for locally advanced (LA) or recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC): KEYNOTE-629Hughes, Brett G. M., Munoz-Couselo, Eva, Mortier, Laurent, Bratland, Ase, Gutzmer, Ralf, Roshdy, Osama, Gonzalez Mendoza, Rene, Schachter, Jacob, Arance, Ana, Grange, Florent, Meyer, Nicolas, Joshi, Abhishek, Billan, Salem, Zhang, Pingye, Gumuscu, Burak, Swaby, Ramona F. and Grob, Jean-Jacques (2021). Phase 2 study of pembrolizumab (pembro) for locally advanced (LA) or recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC): KEYNOTE-629. Annual Meeting of the American-Association-for-Cancer-Research (AACR), Philadelphia Pa, Apr 10-May 21, 2021. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. |
|
2021 Journal Article Neoadjuvant immunotherapy for non-small cell lung cancer: Right drugs, right patient, right time?Ahern, Elizabeth, Solomon, Ben J, Hui, Rina, Pavlakis, Nick, O'Byrne, Ken and Hughes, Brett G M (2021). Neoadjuvant immunotherapy for non-small cell lung cancer: Right drugs, right patient, right time?. Journal for ImmunoTherapy of Cancer, 9 (6) e002248, e002248. doi: 10.1136/jitc-2020-002248 |
|
2021 Journal Article Development of a core outcome set for cutaneous squamous cell carcinoma trials: identification of core domains and outcomesReynolds, K. A., Schlessinger, D. I., Yanes, A. F., Godinez-Puig, V., Chen, B. R., Kurta, A. O., Cotseones, J. K., Chiren, S. G., Iyengar, S., Ibrahim, S. A., Kang, B. Y., Worley, B., Behshad, R., DeHoratius, D. M., Denes, P., Drucker, A. M., Dzubow, L. M., Etzkorn, J. R., Harwood, C. A., Kim, J. Y. S., Lawrence, N., Lee, E. H., Lissner, G. S., Marghoob, A. A., Guminiski, A., Matin, R. N., Mattox, A. R., Mittal, B. B., Thomas, J. R. ... Alam, M. (2021). Development of a core outcome set for cutaneous squamous cell carcinoma trials: identification of core domains and outcomes. British Journal of Dermatology, 184 (6), 1113-1122. doi: 10.1111/bjd.19693 |
|
2021 Conference Publication KEYNOTE-629: Health-related quality of life (HRQoL) with pembrolizumab (pembro) in patients (pts) with locally advanced (LA) or recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC)Bratland, Ase, Munoz-Couselo, Eva, Mortier, Laurent, Roshdy, Osama, Gonzalez, Rene, Schachter, Jacob, Arance, Ana Maria, Grange, Florent, Meyer, Nicolas, Joshi, Abhishek Jagdish, Billan, Salem, Hughes, Brett Gordon Maxwell, Grob, Jean-Jacques, Ramakrishnan, Karthik, Zhang, Eric (Pingye), Gumuscu, Burak, Swaby, Ramona F. and Gutzmer, Ralf (2021). KEYNOTE-629: Health-related quality of life (HRQoL) with pembrolizumab (pembro) in patients (pts) with locally advanced (LA) or recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC). Virtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 04-08, 2021. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1200/JCO.2021.39.15_suppl.9546 |
|
2021 Journal Article EGFR exon 20 insertion mutations: clinicopathological characteristics and treatment outcomes in advanced non–small cell lung cancerLeal, Jose Luis, Alexander, Marliese, Itchins, Malinda, Wright, Gavin M., Kao, Steven, Hughes, Brett G.M., Pavlakis, Nick, Clarke, Stephen, Gill, Anthony J, Ainsworth, Hannah, Solomon, Benjamin and John, Thomas (2021). EGFR exon 20 insertion mutations: clinicopathological characteristics and treatment outcomes in advanced non–small cell lung cancer. Clinical Lung Cancer, 22 (6), e859-e869. doi: 10.1016/j.cllc.2021.04.009 |
|
2021 Journal Article Semiqualitative research protocol to explore cancer care workforce perceptions of the health system response to COVID-19 preparations in Southeast Queensland, AustraliaGasper, Harry, Ahern, Elizabeth, Roberts, Natasha, Chan, Bryan, Hughes, Brett, Kennedy, Glen, Wyld, David, Eastgate, Melissa and Lwin, Zarnie (2021). Semiqualitative research protocol to explore cancer care workforce perceptions of the health system response to COVID-19 preparations in Southeast Queensland, Australia. BMJ Open, 11 (5) e044655, e044655. doi: 10.1136/bmjopen-2020-044655 |
|
2021 Journal Article Highly multiplexed digital spatial profiling of the tumor microenvironment of head and neck squamous cell carcinoma patientsKulasinghe, Arutha, Taheri, Touraj, O'Byrne, Ken, Hughes, Brett G. M., Kenny, Liz and Punyadeera, Chamindie (2021). Highly multiplexed digital spatial profiling of the tumor microenvironment of head and neck squamous cell carcinoma patients. Frontiers in Oncology, 10 607349, 607349. doi: 10.3389/fonc.2020.607349 |
|
2021 Journal Article CCTG BR34: a randomized phase 2 trial of Durvalumab and Tremelimumab with or without platinum-based chemotherapy in patients with metastatic NSCLCLeighl, Natasha B., Laurie, Scott A., Goss, Glenwood D., Hughes, Brett G.M., Stockler, Martin, Tsao, Ming-Sound, Hwang, David M., Joubert, Phillipe, Kulkarni, Swati, Blais, Normand, Joy, Anil A., Mates, Mihaela, Rana, Punam, Yadav, Sunil K., Underhill, Craig, Lee, Christopher, Bradbury, Penelope A., Hiltz, Andrea, Dancey, Janet, Ding, Keyue and Vera-Badillo, Francisco (2021). CCTG BR34: a randomized phase 2 trial of Durvalumab and Tremelimumab with or without platinum-based chemotherapy in patients with metastatic NSCLC. Journal of Thoracic Oncology, 17 (3), 434-445. doi: 10.1016/j.jtho.2021.10.023 |
|
2020 Journal Article CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8+ T cellsBraun, Matthias, Aguilera, Amelia Roman, Sundarrajan, Ashmitha, Corvino, Dillon, Stannard, Kimberley, Krumeich, Sophie, Das, Indrajit, Lima, Luize G., Meza Guzman, Lizeth G., Li, Kunlun, Li, Rui, Salim, Nazhifah, Jorge, Maria Villancanas, Ham, Sunyoung, Kelly, Gabrielle, Vari, Frank, Lepletier, Ailin, Raghavendra, Ashwini, Pearson, Sally, Madore, Jason, Jacquelin, Sebastien, Effern, Maike, Quine, Brodie, Koufariotis, Lambros T., Casey, Mika, Nakamura, Kyohei, Seo, Eun Y., Hölzel, Michael, Geyer, Matthias ... Bald, Tobias (2020). CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8+ T cells. Immunity, 53 (4), 805-823.e15. doi: 10.1016/j.immuni.2020.09.010 |
|
2020 Journal Article Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629)Grob, Jean-Jacques, Gonzalez, Rene, Basset-Seguin, Nicole, Vornicova, Olga, Schachter, Jacob, Joshi, Abhishek, Meyer, Nicolas, Grange, Florent, Piulats, Josep M., Bauman, Jessica R., Zhang, Pingye, Gumuscu, Burak, Swaby, Ramona F. and Hughes, Brett G. M. (2020). Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629). Journal of Clinical Oncology, 38 (25), 2916-2925. doi: 10.1200/JCO.19.03054 |
|
2020 Journal Article Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-inNowak, Anna K, Lesterhuis, W Joost, Kok, Peey-Sei, Brown, Chris, Hughes, Brett GM, Karikios, Deme J, John, Thomas, Kao, Steven C-H, Leslie, Connull, Cook, Alistair M, Pavlakis, Nick, Briscoe, Karen, O'Byrne, Kenneth J, Karapetis, Christos S, Lam, Wei-Sen, Langford, Ailsa, Yip, Sonia and Stockler, Martin R (2020). Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. The Lancet Oncology, 21 (9), 1213-1223. doi: 10.1016/S1470-2045(20)30462-9 |
|
2020 Conference Publication Abstract 3384: characterization of the tumor microenvironment and liquid biopsy in head and neck and non-small cell lung cancerKulasinghe, Arutha, Kapeleris, Joanna, Kenny, Liz, Hughes, Brett, Warkiani, Majid, Vela, Ian, Thiery, Jean-Paul, O'Byrne, Ken and Punyadeera, Chamindie (2020). Abstract 3384: characterization of the tumor microenvironment and liquid biopsy in head and neck and non-small cell lung cancer. AACR Annual Meeting 2020, Philadelphia, PA USA, 27-28 April 2020 and 22-24 June 2020. Philadelphia, PA USA: American Association for Cancer Research. doi: 10.1158/1538-7445.am2020-3384 |
|
2020 Conference Publication Limited benefit of adjuvant chemotherapy in resected Epidermal Growth Factor Receptor (EGFR) positive non-small cell lung cancer (NSCLC)O'Leary, Connor, Fletcher, James, Yuile, Alexander, Xu, Wen, Ladwa, Rahul, McGrath, Margaret, Pavlakis, Nick, Hughes, Brett, McCaffery, Elizabeth and O'Byrne, Kenneth (2020). Limited benefit of adjuvant chemotherapy in resected Epidermal Growth Factor Receptor (EGFR) positive non-small cell lung cancer (NSCLC). Medical Oncology Group of Australia Annual Scientific Meeting, Virtual, Australia, 14-21 August 2020. Chichester, West Sussex, United Kingdom: Wiley-Blackwell. |
|
2020 Journal Article Oral HPV16 DNA as a screening tool to detect early oropharyngeal squamous cell carcinomaTang, Kai D., Vasani, Sarju, Menezes, Lilian, Taheri, Touraj, Walsh, Laurence J., Hughes, Brett G.M., Frazer, Ian H., Kenny, Liz, Scheper, Gert C. and Punyadeera, Chamindie (2020). Oral HPV16 DNA as a screening tool to detect early oropharyngeal squamous cell carcinoma. Cancer Science, 111 (10) cas.14585, 3854-3861. doi: 10.1111/cas.14585 |
